Adamas Pharmaceuticals, Inc. (ADMS) Financial Statements (2024 and earlier)

Company Profile

Business Address 1900 POWELL ST., SUITE 1000
EMERYVILLE, CA 94608
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2021
MRQ
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 83,400132,600210,870176,400135,900120,000
Cash and cash equivalents 71,66065,77456,60591,31623,73533,104
Short-term investments 11,70566,833154,26582,12689,91773,691
Other undisclosed cash, cash equivalents, and short-term investments 35(7) 2,95822,24813,205
Receivables 15,5427,0296,3511,3749625,577
Inventory, net of allowances, customer advances and progress billings 7,2945,2675,1211,704  
Inventory 7,2945,2675,1211,704  
Prepaid expense 3,1262,6242,9692,6381,279545
Other current assets 22983763171,05715
Other undisclosed current assets 2,1452,7172,299(2,958)(22,211)(12,950)
Total current assets: 111,736150,320228,373179,175116,987113,187
Noncurrent Assets
Operating lease, right-of-use asset 6,6578,048
Property, plant and equipment 1,5982,4493,6523,1323,1562,353
Long-term investments and receivables    2,99122,29213,165
Long-term investments    2,99122,29213,165
Other noncurrent assets    8783838
Other undisclosed noncurrent assets 381,3412,789   
Total noncurrent assets: 8,29311,8386,4417,00125,48615,556
TOTAL ASSETS: 120,029162,158234,814186,176142,473128,743
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 29,30823,04923,76416,2639,45611,509
Accounts payable 2,1446,9326,5703,8783,5893,052
Accrued liabilities 27,16416,11717,19412,3855,8678,457
Debt 3,6572,041    
Other liabilities 1,9021,858512344287298
Total current liabilities: 34,86726,94824,27616,6079,74311,807
Noncurrent Liabilities
Long-term debt and lease obligation 132,760133,946117,457102,647  
Long-term debt, excluding current maturities 126,307125,674117,457102,647  
Liabilities, other than long-term debt 2,3782,1573,196796547749
Other liabilities 2,3782,1573,196796547749
Operating lease, liability 6,4538,272
Total noncurrent liabilities: 135,138136,103120,653103,443547749
Total liabilities: 170,005163,051144,929120,05010,29012,556
Equity
Equity, attributable to parent (49,976)(893)89,88566,126132,183116,187
Common stock 343332282723
Additional paid in capital 455,277446,942432,815277,964254,558178,473
Accumulated other comprehensive income (loss)  16(264)(167)(193)(158)
Accumulated deficit (505,287)(447,884)(342,698)(211,699)(122,209)(62,151)
Total equity: (49,976)(893)89,88566,126132,183116,187
TOTAL LIABILITIES AND EQUITY: 120,029162,158234,814186,176142,473128,743

Income Statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 74,46154,63734,0465715721,916
Revenue, net571  
Cost of revenue
(Cost of Goods and Services Sold)
 (2,038)(2,469)(633)(17)  
Gross profit: 72,42352,16833,4135545721,916
Operating expenses (116,587)(144,403)(148,435)(88,497)(61,556)(59,353)
Other undisclosed operating income    17  
Operating loss: (44,164)(92,235)(115,022)(87,926)(60,984)(57,437)
Nonoperating income
(Investment Income, Nonoperating)
 135     
Interest and debt expense (13,987)(15,044)(19,092)(4,645)  
Other undisclosed income from continuing operations before equity method investments, income taxes 6132,0933,1151,351811363
Loss from continuing operations before income taxes: (57,403)(105,186)(130,999)(91,220)(60,173)(57,074)
Income tax benefit    1,7301155,272
Loss from continuing operations: (57,403)(105,186)(130,999)(89,490)(60,058)(51,802)
Loss before gain (loss) on sale of properties:(57,403)(105,186)(130,999)(89,490)(60,058)(51,802)
Net loss available to common stockholders, diluted: (57,403)(105,186)(130,999)(89,490)(60,058)(51,802)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (57,403)(105,186)(130,999)(89,490)(60,058)(51,802)
Comprehensive loss: (57,403)(105,186)(130,999)(89,490)(60,058)(51,802)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (16)280(97)26(35)22
Comprehensive loss, net of tax, attributable to parent: (57,419)(104,906)(131,096)(89,464)(60,093)(51,780)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: